scholarly journals Cochrane Corner: Coronavirus (COVID-19): are pre-existing cardiovascular comorbidities associated with COVID-19 severity and what is the rate of subsequent cardiovascular complications?

2021 ◽  
Vol 13 (2) ◽  
pp. 189
Author(s):  
Vanessa Jordan
Keyword(s):  
Cardiovascular Complications ◽  
Cardiovascular Comorbidities

scholarly journals Adverse Cardiovascular Effects of Anti-COVID-19 Drugs

2021 ◽  
Vol 12 ◽  
Author(s):  
Dongling Liu ◽  
Xiang Zeng ◽  
Zufeng Ding ◽  
Fenghua Lv ◽  
Jawahar L. Mehta ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Adverse Effects ◽  
Myocardial Injury ◽  
Cardiovascular Effects ◽  
Cardiovascular Complications ◽  
Therapeutic Interventions ◽  
Risk Of Death ◽  
Cardiovascular Comorbidities ◽  
Global Pandemic ◽  
Acute Myocardial Injury

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or COVID-19 infection is the cause of the ongoing global pandemic. Mortality from COVID-19 infection is particularly high in patients with cardiovascular diseases. In addition, COVID-19 patients with preexisting cardiovascular comorbidities have a higher risk of death. Main cardiovascular complications of COVID-19 are myocardial infarction, myocarditis, acute myocardial injury, arrhythmias, heart failure, stroke, and venous thromboembolism. Therapeutic interventions in terms of drugs for COVID-19 have many cardiac adverse effects. Here, we review the relative therapeutic efficacy and adverse effects of anti-COVID-19 drugs.

scholarly journals COVID-19 and Congenital Heart Disease: Results from a Nationwide Survey

2020 ◽  
Vol 9 (6) ◽  
pp. 1774 ◽  
Author(s):  
Jolanda Sabatino ◽  
Paolo Ferrero ◽  
Massimo Chessa ◽  
Francesco Bianco ◽  
Paolo Ciliberti ◽  
...  
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Congenital Heart ◽  
Case Fatality ◽  
Nationwide Survey ◽  
High Volume ◽  
Cardiovascular Complications ◽  
High Risk Population ◽  
Cardiovascular Comorbidities ◽  
Novel Coronavirus

Background. The pandemic of Novel Coronavirus Disease 2019 (COVID-19) is challenging, given the large number of hospitalized patients. Cardiovascular co-morbidities are linked to a higher mortality risk. Thus, patients with Congenital Heart Disease (CHD) might represent a high-risk population. Nevertheless, no data about them are available, yet. Hence, we conducted a nationwide survey to assess clinical characteristics and outcomes in patients with congenital heart disease affected by COVID-19. Methods and Results. This is a multi-centre, observational, nationwide survey, involving high-volume Italian CHD centres. COVID-19 diagnosis was defined as either “clinically suspected” or “confirmed”, where a severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) test had been performed and was positive. Cardiovascular comorbidities were observed among adult patients—atrial fibrillation (seven; 9%), hypertension (five; 7%), obesity (seven; 9%) and diabetes (one; 1%)—but were absent among children. Cardiovascular complications were mainly observed in the “confirmed” COVID-19+ group, consisting of heart failure (9%), palpitations/arrhythmias (3%), stroke/TIA (3%) and pulmonary hypertension (3%). Cardiovascular symptoms such as chest pain (1%), myocardial injury (1%) and pericardial effusion (1%) were also recorded. On the contrary, CHD patients from the clinically suspected COVID-19 group presented no severe symptoms or complications. Conclusions. Despite previous reports pointing to a higher case-fatality rate among patients with cardiovascular co-morbidities, we observed a mild COVID-19 clinical course in our cohort of CHD patients. Although these results should be confirmed in larger cohorts to investigate the underlying mechanisms, the findings of low cardiovascular complications rates and no deaths are reassuring for CHD patients.

scholarly journals Findings on the relationship between cardiovascular disease and coronavirus disease 2019: a systematic review

2020 ◽  
Author(s):  
Yuri Henrique da Silva1 ◽  
José Gildo de Moura Monteiro Júnior ◽  
Rosângela Ferreira Frade de Araújo
Keyword(s):  
Systematic Review ◽  
Cardiovascular Disease ◽  
Cardiac Injury ◽  
The Elderly ◽  
Cardiovascular Complications ◽  
Cardiac Insufficiency ◽  
Risk Of Death ◽  
Coronary Syndrome ◽  
Cardiovascular Comorbidities ◽  
Number Of Patients

Abstract Coronavirus disease 2019 (COVID-19) presents as the main cause of death, respiratory and heart failures, especially in the elderly, immunosuppressed, and those with cardiovascular comorbidities. Therefore, a better understanding of these findings is needed. A systematic review was carried out looking for articles published between December 2019 and May 2020 on the MEDLINE / PubMed search platform using the following descriptors: ((((((((("cardiovascular disease") OR ("acute myocardial infarction")) OR ("coronary artery disease")) OR ("acute coronary syndrome")) OR ("atherosclerosis")) OR ("cardiac insufficiency")) OR ("pericarditis")) OR ("myocarditis")) AND ("COVID-19")) OR ("SARS-CoV-2")and considering inclusion and exclusion criteria.40% of patients infected with SARS-CoV-2 had hypertension or other cardiovascular comorbidities, while 27% presented cardiovascular complications, mainly acute cardiac injury, arrhythmia and heart failure. The hypotheses of involvement of an intense inflammatory response, decreased immunity and greater expression of ACE2 in the heart, associated with more severe heart conditions, were discussed in this study. The increase in cardiac and inflammatory markers was associated with worse clinical outcomes and risk of death, confirming the need to evaluate them since admission to the hospital. The 10 articles analyzed presented as a limitation the small number of patients inserted, to the detriment of the pandemic state. We warned about the need for better clinical management of patients with cardiovascular comorbidities, and the importance of including this group among the first to be immunized, aiming at reducing the number of fatal cases due to infection. Studies with greater coverage are needed for a better comprehension of the topics discussed here.

scholarly journals Life-Time Risk, Screening and The Cost of Cardiovascular Comorbidities in CKD Patients

PRILOZI ◽  
2015 ◽  
Vol 36 (2) ◽  
pp. 85-90
Author(s):  
Carmine Zoccali ◽  
Samar Abd ElHafeez ◽  
Evangelia Dounousi ◽  
Rossana Anastasi ◽  
Giovanni Tripepi ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Life Time ◽  
Epidemiological Data ◽  
Cardiovascular Complications ◽  
Insurance Company ◽  
Risk Of Death ◽  
Cardiovascular Comorbidities ◽  
Large Member ◽  
The Cost ◽  
Risk Equivalent

Abstract CKD is a problem of epidemic dimension. The risk of death and cardiovascular complications in this condition is of the same order of that by myocardial infarction, which qualifies CKD as “risk equivalent”. Calculations made on the basis of the epidemiological data of the MONICA-Augsburg study and analyses of the costs of myocardial infarction in a large health insurance company in Germany show that the economic burden of cardiovascular comorbidities with CKD in this country is substantial. These estimates, which may be valid also for other large member states of the European Community, represent a call for studies looking at the cost-effectiveness of preventive interventions aimed at reducing the risk for CKD and at lowering the concerning incidence rate of death and disability due to CKD-triggered cardiovascular complications in CKD patients.

scholarly journals Natural History of Hypertension in Turner Syndrome During a 12-Year Pragmatic Interventional Study

Hypertension ◽  
2020 ◽  
Vol 76 (5) ◽  
pp. 1608-1615
Author(s):  
Kristian Sandahl ◽  
Jan Wen ◽  
Mogens Erlandsen ◽  
Niels H. Andersen ◽  
Claus H. Gravholt
Keyword(s):  
Heart Rate ◽  
Turner Syndrome ◽  
Pulse Pressure ◽  
Antihypertensive Treatment ◽  
Cardiovascular Complications ◽  
Contributing Factors ◽  
Interventional Study ◽  
Cardiovascular Comorbidities ◽  
Number Of Patients ◽  
Increased Risk

Turner syndrome is caused by complete or partial X monosomy in some or all cells. Cardiovascular complications are dominant, including increased blood pressure (BP), leading to early-onset hypertension. The aim is to describe the debut, development, and treatment of hypertension in Turner syndrome during a 12-year pragmatic interventional study to help identify risk factors associated with hypertension. One hundred and two women (aged 38±11 years, range: 18–62 years) with Turner syndrome verified by karyotyping (45, X: n=58 [57%]) were included consecutively. Ambulatory BPs were recorded over 24 hours with oscillometric measurements every 20 minutes. Antihypertensive treatment was recommended if the BP was above 135/85 mm Hg during the daytime. Overall, systolic BP, diastolic BP, and pulse pressure increased during the study, while heart rate decreased. The number of patients treated with antihypertensive medicine increased from 29 (28.71%) at baseline to 34 (53.13%) at the end of study. Twenty-four–hour systolic BP and 24-hour pulse pressure increased significantly with age, while 24-hour heart rate decreased with age, and diastolic BP was insignificantly affected by age. Antihypertensive treatment lowered systolic BP (24-hour: −5 mm Hg), diastolic BP (24-hour: −5 mm Hg), and diminished the pulse pressure (24-hour: −6 mm Hg) but did not affect nighttime systolic BP. Antihypertensive treatment did not affect heart rate. Our study showed that both systolic and diastolic BP increases significantly in women with Turner syndrome resulting in an increased risk of cardiovascular comorbidities. This increment should be considered of multifactorial origin with many contributing factors which is supported by our results.

scholarly journals COVID-19 Related Cardiovascular Comorbidities and Complications in Critically Ill Patients: A Systematic Review and Meta-analysis

2021 ◽  
Vol 15 ◽  
pp. 117954842199232
Author(s):  
Michael Koeppen ◽  
Peter Rosenberger ◽  
Harry Magunia
Keyword(s):  
Systematic Review ◽  
Intensive Care Unit ◽  
Intensive Care ◽  
Critically Ill ◽  
Observational Studies ◽  
Meta Analysis ◽  
Cardiovascular Complications ◽  
Cardiovascular Comorbidity ◽  
Cardiovascular Comorbidities ◽  
The Impact

Objective: This systematic-review and meta-analysis aimed to assess the prevalence of cardiovascular comorbidities and complications in ICU-admitted coronavirus disease 2019 (COVID-19) patients. Data sources: PubMed and Web of Science databases were referenced until November 25, 2020. Data extraction: We extracted retrospective and prospective observational studies on critically ill COVID-19 patients admitted to an intensive care unit. Only studies reporting on cardiovascular comorbidities and complications during ICU therapy were included. Data synthesis: We calculated the pooled prevalence by a random-effects model and determined heterogeneity by Higgins’ I2 test. Results: Of the 6346 studies retrieved, 29 were included in this review. The most common cardiovascular comorbidity was arterial hypertension (50%; 95% confidence interval [CI], 0.42-058; I2 = 94.8%, low quality of evidence). Among cardiovascular complications in the ICU, shock (of any course) was most common, being present in 39% of the patients (95% CI, 0.20-0.59; I2 = 95.6%; 6 studies). Seventy-four percent of patients in the ICU required vasopressors to maintain target blood pressure (95% CI, 0.58-0.88; I2 = 93.6%; 8 studies), and 30% of patients developed cardiac injury in the ICU (95% CI, 0.19-0.42; I2 = 91%; 14 studies). Severe heterogeneity existed among the studies. Conclusions: Cardiovascular complications are common in patients admitted to the intensive care unit for COVID-19. However, the existing evidence is highly heterogeneous in terms of study design and outcome measurements. Thus, prospective, observational studies are needed to determine the impact of cardiovascular complications on patient outcome in critically ill COVID-19 patients.

scholarly journals Prognostic Value of Cardiovascular Biomarkers in COVID-19: A Review

Viruses ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 527 ◽  
Author(s):  
Maryam Aboughdir ◽  
Thomas Kirwin ◽  
Ashiq Abdul Khader ◽  
Brian Wang
Keyword(s):  
Risk Factors ◽  
Myocardial Injury ◽  
Cardiac Injury ◽  
Cardiovascular Complications ◽  
Adverse Outcomes ◽  
Cardiovascular Comorbidities ◽  
Increased Risk ◽  
High Prevalence ◽  
Cardiovascular Biomarkers ◽  
Worse Prognosis

In early December 2019, the coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first emerged in Wuhan, China. As of May 10th, 2020, a total of over 4 million COVID-19 cases and 280,000 deaths have been reported globally, reflecting the raised infectivity and severity of this virus. Amongst hospitalised COVID-19 patients, there is a high prevalence of established cardiovascular disease (CVD). There is evidence showing that COVID-19 may exacerbate cardiovascular risk factors and preexisting CVD or may lead to cardiovascular complications. With intensive care units operating at maximum capacity and such staggering mortality rates reported, it is imperative during this time-sensitive COVID-19 outbreak to identify patients with an increased risk of adverse outcomes and/or myocardial injury. Preliminary findings from COVID-19 studies have shown the association of biomarkers of acute cardiac injury and coagulation with worse prognosis. While these biomarkers are recognised for CVD, there is emerging prospect that they may aid prognosis in COVID-19, especially in patients with cardiovascular comorbidities or risk factors that predispose to worse outcomes. Consequently, the aim of this review is to identify cardiovascular prognostic factors associated with morbidity and mortality in COVID-19 and to highlight considerations for incorporating laboratory testing of biomarkers of cardiovascular performance in COVID-19 to optimise outcomes.

scholarly journals Dampak Coronavirus Disease 2019 terhadap Sistem Kardiovaskular

e-CliniC ◽  
2020 ◽  
Vol 8 (2) ◽  
Author(s):  
Herick A. Willim ◽  
Infan Ketaren ◽  
Alice I. Supit
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Angiotensin Converting Enzyme ◽  
Myocardial Injury ◽  
Clinical Manifestations ◽  
Cardiovascular Complications ◽  
Converting Enzyme ◽  
Angiotensin Converting Enzyme 2 ◽  
Cardiovascular Comorbidity ◽  
Cardiovascular Comorbidities ◽  
Severe Manifestation

Abstract: Coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection has become a pandemic. Patient with cardiovascular comorbidity has a higher risk of suffering more severe manifestation of COVID-19 associated with a higher mortality. Although dominated by respiratory clinical manifestation, COVID-19 may also cause severe cardiovascular disorders. Angiotensin converting enzyme 2 (ACE2) acts as a receptor of SARS-CoV-2. Patients of COVID-19 with cardiovascular comorbidities may experience more severe clinical manifestations, presumably due to higher ACE2 expression in this population. Cardiovascular complications in COVID-19 may include myocardial injury, myocarditis, acute myocardial infarction, acute heart failure, thromboembolism, and arrhythmias. Therefore, optimization of conservative medical therapy needs to be prioritized in patients with cardiovascular comorbidities. Emergency intervention can be considered in certain cases with hemodynamic instability.Keywords: cardiovascular system, COVID-19, SARS-CoV-2, ACE2 Abstrak: Coronavirus disease 2019 (COVID-19) telah merupakan pandemi yang disebabkan oleh infeksi Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Pasien dengan komorbid kardiovaskular berisiko lebih tinggi untuk mengalami manifestasi yang lebih berat jika terinfeksi COVID-19 dan berhubungan dengan mortalitas yang lebih tinggi. Meskipun didominasi oleh manifestasi klinis respiratorik, COVID-19 juga dapat menyebabkan gangguan kardiovaskular yang berat. Angiotensin converting enzyme 2 (ACE2) berperan sebagai reseptor SARS-CoV-2. Diduga pasien dengan penyakit kardiovaskular dapat bermanifestasi klinis lebih berat karena ekspresi ACE2 yang lebih tinggi pada populasi ini. Komplikasi kardiovaskular pada COVID-19 dapat meliputi jejas miokardium, miokarditis, infark miokard akut, gagal jantung akut, tromboemboli, dan aritmia. Pada pasien dengan komorbid kardiovaskular, optimalisasi terapi medis konservatif perlu diprioritaskan. Tindakan intervensi darurat dapat dipertimbangkan pada kasus tertentu dengan instabilitas hemodinamik.Kata kunci: sistem kardiovaskular, COVID-19, SARS-CoV-2, ACE2

Update CACOCA Trial (cardiovascular complications of cancer treatment)

Pneumologie ◽  
2014 ◽  
Vol 68 (05) ◽  
Author(s):  
F Kocher ◽  
B Föger ◽  
M Fiegl ◽  
M Fridrik ◽  
G Gastl ◽  
...  
Keyword(s):  
Cancer Treatment ◽  
Cardiovascular Complications
Sign in / Sign up

Export Citation Format

Share Document